Therapeutic approach

Our innovation is a proprietary, first-in-class disease modifying osteoarthritis drug (DMOAD) targeting the disease directly at the source: the arthritic joint.

Our technology simultaneously addresses several unmet needs in OA such as cartilage degeneration, bone resorption, inflammation and pain.

Our frontrunner compound, CRN-001, targets a microRNA (miR-574-5p) regulating OA pathogenesis and is applied directly to the affected joint, with a strong and long-lasting benefit and a very low risk of systemic side effects.

CRN-001 is in advanced preclinical development and has shown efficacy in relevant in-vitro and in-vivo OA models.